ReviewDiabetes technology & therapeutics2023
Coverage for Continuous Glucose Monitoring for Individuals with Type 2 Diabetes Treated with Nonintensive Therapies: An Evidence-Based Approach to Policymaking.
Review in Diabetes technology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Continuous glucose monitoring in noninsulin-treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta-analysis of randomised controlled trials.Diabetes, obesity & metabolism · 2025Pooled it
- Use of continuous glucose monitoring in non-intensively managed type 2 diabetes: a Saudi Arabian consensus.Frontiers in endocrinology · 2025Guideline
- Integrating Pharmacists into CGM-Enabled Digital Diabetes Care: Advancing Personalized and Data-Driven Management.Healthcare (Basel, Switzerland) · 2026Review
- Unlocking the Value of Patient Self-Monitoring Technologies: A Multi-Country Framework to Calibrate Payer and HTA Coverage and Reimbursement Considerations with Innovation.Journal of health economics and outcomes research · 2026Article
- Article
- Expert Opinion Statement on Continuous Glucose Monitoring in Type 2 Diabetes in the Arab Gulf Region.Journal of diabetes science and technology · 2025Review
- Addition of continuous glucose monitoring to glucagon-like peptide 1 receptor agonist treatment for type 2 diabetes mellitus - An economic evaluation.Journal of managed care & specialty pharmacy · 2025Article
- Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Health Care Costs: A Comparative Analysis by Insurance Type.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure.Journal of managed care & specialty pharmacy · 2024Article
- Innovation is the driver behind quality improvements in diabetes care delivery.Journal of managed care & specialty pharmacy · 2024Article
- Review
- Continuous Glucose Monitor: Reclaiming Type 2 Diabetes Self-efficacy and Mitigating Disparities.Journal of the Endocrine Society · 2024Article
- The Glucose Management Indicator: Time to Change Course?Diabetes care · 2024Review
- AMCP Market Insights Health Plan Best Practice: Implementing continuous glucose monitoring to improve patient outcomes in diabetes.Journal of managed care & specialty pharmacy · 2024Review
- Techniques for Implementing Continuous Glucose Monitoring in Primary Care: Key CGM Updates and Highlights from the ATTD 2024 Conference [Podcast].Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Roadmap to the Effective Use of Continuous Glucose Monitoring: Innovation, Investigation, and Implementation.Diabetes spectrum : a publication of the American Diabetes Association · 2023Article
- Use of flash glucose monitoring is associated with HbA1c reduction in type 2 diabetes managed with basal insulin in Canada: A real-world prospective observational study.Diabetes & vascular disease researchObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Numerous studies have demonstrated the clinical benefits of continuous glucose monitoring (CGM) in individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) who are treated with intensive insulin regimens. Based on this evidence, CGM is now a standard of care for individuals within these diabetes populations and widely covered by commercial and public insurers. Moreover, recent clinical guidelines from the American Diabetes Association and American Association of Clinical Endocrinology now endorse CGM use in individuals treated with nonintensive insulin regimens. However, despite increasing evidence supporting CGM use for individuals treated with less-intensive insulin therapy or noninsulin medications, insurance coverage is limited or nonexistent. This narrative review reports key findings from recent randomized, observational, and retrospective studies investigating use of CGM in T2D individuals treated with basal insulin only and/or noninsulin therapies and presents an evidence-based rationale for expanding access to CGM within this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.